Neurocrine Biosciences Company Profile (NASDAQ:NBIX)

About Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences logoNeurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:NBIX
  • CUSIP: 64125C10
  • Web:
  • Market Cap: $4.31 billion
  • Outstanding Shares: 88,074,000
Average Prices:
  • 50 Day Moving Avg: $51.15
  • 200 Day Moving Avg: $45.68
  • 52 Week Range: $37.35 - $55.38
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -35.17
  • P/E Growth: -0.46
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.82 per share
  • Price / Book: 17.34
  • EBIDTA: ($204,780,000.00)
  • Return on Equity: -32.04%
  • Return on Assets: -28.53%
  • Current Ratio: 13.42%
  • Quick Ratio: 13.42%
  • Average Volume: 1.29 million shs.
  • Beta: 0.55
  • Short Ratio: 4.36

Frequently Asked Questions for Neurocrine Biosciences (NASDAQ:NBIX)

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.23. During the same period in the prior year, the company posted ($0.22) EPS. View Neurocrine Biosciences' Earnings History.

Where is Neurocrine Biosciences' stock going? Where will Neurocrine Biosciences' stock price be in 2017?

18 analysts have issued 1 year price targets for Neurocrine Biosciences' stock. Their forecasts range from $55.00 to $100.00. On average, they anticipate Neurocrine Biosciences' stock price to reach $67.75 in the next year. View Analyst Ratings for Neurocrine Biosciences.

What are analysts saying about Neurocrine Biosciences stock?

Here are some recent quotes from research analysts about Neurocrine Biosciences stock:

  • 1. Cowen and Company analysts commented, "NBIX remains well funded, ending Q4 with $352MM in cash." (2/15/2017)
  • 2. Robert W. Baird analysts commented, "No change to outlook heading into Ingrezza approval. Neurocrine reported a solid end to the year, modestly beating estimates on lower-than-expected opex. Though we are only a few weeks into 2017, it has already been a busy year for NBIX. Expect the year to continue to bring multiple updates, from potential approval of Ingrezza in TD and Tourette data in May to Phase 3 UF data for elagolix near year-end, an elagolix NDA submission, advances in CAH and essential tremor, and FDA discussions on newly licensed opicapone' Earnings and spend in-line, expect accelerations into launch. 4Q16 EPS of ($0.51) modestly beat our/consensus estimates of ($0.54)/($0.57), respectively, due to lower than projected operating expenses. Looking ahead to 2017, management expects opex to increase to about $230M-$240M due activities surrounding the launch of Ingrezza." (2/15/2017)
  • 3. Needham & Company LLC analysts commented, "Company continues to prepare for Ingrezza launch ahead of 4/11/17 PDUFA date. We expect approval based on strength of Phase 3 data, followed by launch ~6wks later. We believe Boxed Warning/ REMS are possible. Phase 2 pediatric Tourette Syndrome (TS) data are expected May 2017 (was Apr). Given efficacy trend observed in adult Phase 2 TS, we believe Ingrezza will likely be active in pediatric TS as well. Elagolix NDA submission for Endometriosis by Abbvie is expected 3Q17 (was 2H17), triggering a $30M payment to Neurocrine. Phase 3 results in Uterine Fibroids are expected by YE17. We believe stock is attractive ahead of near term events. BUY." (2/10/2017)
  • 4. HC Wainwright analysts commented, "We expect FDA to agree in early 2017 that Atara has demonstrated comparability between clinical batches of ATA-129, or EBV-CTL, and the prior material produced at MSKCC, paving the way for Phase 3 start. We believe comparability data will include the number of cells to administer, cytoreactivity, cell storage time, restriction studies (HLA types), variability based on release criteria, and the methods by which data are collected. CMC amendment standard for new clinical material Importantly, a CMC amendment is standard practice for an IND when new clinical material is introduced; therefore, we view Atara’s process as normal." (1/18/2017)
  • 5. Jefferies Group LLC analysts commented, "While the study showed a stat sig improvement on the Clinical Global Impression of Change scale (CGI; p=0.015), the study did not reach stat sig on the 1EP of Yale Global Tic Severity Scale (YGTSS; p=0.18). No further trial details were released. Although a setback, we note that this does not directly read through to the pediatric study readout expected in April." (1/18/2017)

Who are some of Neurocrine Biosciences' key competitors?

Who owns Neurocrine Biosciences stock?

Neurocrine Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (13.81%), Vanguard Group Inc. (7.73%), BlackRock Inc. (5.78%), Janus Capital Management LLC (5.00%), Perceptive Advisors LLC (3.86%) and BB Biotech AG (3.68%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, Timothy P Coughlin, W Thomas Mitchell and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

Who sold Neurocrine Biosciences stock? Who is selling Neurocrine Biosciences stock?

Neurocrine Biosciences' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, OppenheimerFunds Inc., Marshall Wace LLP, American Century Companies Inc., Westfield Capital Management Co. LP, JPMorgan Chase & Co., Hood River Capital Management LLC and Alliancebernstein L.P.. Company insiders that have sold Neurocrine Biosciences stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Dimitri E Grigoriadis, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, Timothy P Coughlin and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.

Who bought Neurocrine Biosciences stock? Who is buying Neurocrine Biosciences stock?

Neurocrine Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Wellington Management Group LLP, Janus Capital Management LLC, Goldman Sachs Group Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Redmile Group LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Neurocrine Biosciences.

How do I buy Neurocrine Biosciences stock?

Shares of Neurocrine Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Neurocrine Biosciences stock cost?

One share of Neurocrine Biosciences stock can currently be purchased for approximately $48.89.

Analyst Ratings

Consensus Ratings for Neurocrine Biosciences (NASDAQ:NBIX) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 16 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $67.75 (38.58% upside)

Analysts' Ratings History for Neurocrine Biosciences (NASDAQ:NBIX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017ValuEngineDowngradeSell -> Strong SellLowView Rating Details
5/24/2017Oppenheimer Holdings Inc.Set Price TargetBuy$70.00MediumView Rating Details
5/24/2017Piper Jaffray CompaniesSet Price TargetBuy$68.00MediumView Rating Details
5/24/2017JPMorgan Chase & Co.Set Price TargetBuy$57.00MediumView Rating Details
5/25/2017BMO Capital MarketsReiterated RatingOutperform$75.00LowView Rating Details
5/25/2017Leerink SwannReiterated RatingOutperform$68.00 -> $66.00LowView Rating Details
5/24/2017Needham & Company LLCReiterated RatingBuy$62.00 -> $58.00LowView Rating Details
5/22/2017Jefferies Group LLCReiterated RatingBuy$67.00MediumView Rating Details
5/15/2017Bank of America CorpReiterated RatingBuy$70.00MediumView Rating Details
5/2/2017Barclays PLCBoost Price TargetOverweight$60.00 -> $70.00LowView Rating Details
4/14/2017Robert W. BairdReiterated RatingOutperform$66.00N/AView Rating Details
3/7/2017Cantor FitzgeraldReiterated RatingOverweight$80.00N/AView Rating Details
2/16/2017HC WainwrightBoost Price TargetPositive$80.00 -> $100.00N/AView Rating Details
2/15/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
2/10/2017ICAPReiterated RatingOutperform$55.00N/AView Rating Details
1/27/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
1/19/2017Deutsche Bank AGReiterated RatingBuy$65.00 -> $62.00N/AView Rating Details
11/22/2016Citigroup IncInitiated CoverageMarket Perform$55.00N/AView Rating Details
11/2/2015NomuraBoost Price TargetBuy$34.00 -> $43.00N/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for Neurocrine Biosciences (NASDAQ:NBIX)
Earnings by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
Earnings History by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 17($0.67)($0.90)$3.00 millionViewListenView Earnings Details
2/14/2017Q416($0.55)($0.51)$4.55 millionViewListenView Earnings Details
11/2/2016Q316($0.57)($0.43)ViewN/AView Earnings Details
5/5/2016Q1($0.29)($0.22)$15.43 million$15.00 millionViewN/AView Earnings Details
2/11/2016Q415($0.32)($0.34)$3.33 millionViewListenView Earnings Details
10/29/2015Q315($0.25)($0.40)$6.66 millionViewListenView Earnings Details
7/29/2015Q2($0.29)($0.28)$0.41 millionViewListenView Earnings Details
4/30/2015Q115($0.30)($0.01)$19.76 millionViewN/AView Earnings Details
2/9/2015Q414($0.24)($0.26)ViewN/AView Earnings Details
11/3/2014Q314($0.21)($0.21)ViewN/AView Earnings Details
8/6/2014Q214($0.18)($0.18)$0.12 millionViewN/AView Earnings Details
4/30/2014Q114($0.19)($0.17)$0.78 millionViewN/AView Earnings Details
2/6/2014Q413($0.17)($0.16)$0.79 million$0.73 millionViewN/AView Earnings Details
10/29/2013Q313($0.20)($0.17)$0.79 million$0.73 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.20)($0.18)$0.77 million$0.73 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.18)$1.07 million$0.70 millionViewListenView Earnings Details
2/8/2013Q4 2012($0.08)$0.14$9.43 million$21.90 millionViewListenView Earnings Details
10/31/2012Q312($0.05)($0.05)$10.28 million$9.40 millionViewN/AView Earnings Details
7/31/2012($0.03)($0.01)ViewN/AView Earnings Details
5/2/2012($0.01)ViewN/AView Earnings Details
10/31/2011$0.19$0.56ViewN/AView Earnings Details
7/28/2011$0.04$0.04ViewN/AView Earnings Details
5/3/2011$0.05$0.05ViewN/AView Earnings Details
2/10/2011$0.04$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Neurocrine Biosciences (NASDAQ:NBIX)
2017 EPS Consensus Estimate: ($2.30)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.89)($0.54)($0.65)
Q2 20174($0.68)($0.62)($0.65)
Q3 20174($0.72)($0.28)($0.50)
Q4 20174($0.69)($0.28)($0.50)
(Data provided by Zacks Investment Research)


Dividend History for Neurocrine Biosciences (NASDAQ:NBIX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Neurocrine Biosciences (NASDAQ:NBIX)
Insider Ownership Percentage: 4.80%
Institutional Ownership Percentage: 97.60%
Insider Trades by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
Insider Trades by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/23/2017Dimitri E GrigoriadisInsiderSell10,000$53.39$533,900.00View SEC Filing  
5/19/2017Malcolm Lloyd-SmithInsiderSell9,960$53.63$534,154.80View SEC Filing  
5/5/2017Corinne H NevinnyDirectorSell5,000$53.98$269,900.00View SEC Filing  
5/2/2017Dimitri E GrigoriadisInsiderSell10,000$55.00$550,000.00View SEC Filing  
5/2/2017Kevin Charles GormanCEOSell21,739$53.23$1,157,166.97View SEC Filing  
5/1/2017Kyle GanoInsiderSell15,000$54.00$810,000.00View SEC Filing  
4/12/2017Haig P BozigianInsiderSell13,065$50.42$658,737.30View SEC Filing  
4/12/2017Kevin Charles GormanCEOSell19,596$50.42$988,030.32View SEC Filing  
2/7/2017Malcolm Lloyd-SmithInsiderSell116$44.61$5,174.76View SEC Filing  
2/6/2017Dimitri E GrigoriadisInsiderSell727$43.13$31,355.51View SEC Filing  
2/6/2017Kevin Charles GormanCEOSell3,010$43.18$129,971.80View SEC Filing  
2/6/2017Timothy P CoughlinCFOSell963$43.14$41,543.82View SEC Filing  
2/3/2017Christopher Flint ObrienInsiderSell1,500$42.50$63,750.00View SEC Filing  
2/3/2017Kevin Charles GormanCEOSell3,125$42.55$132,968.75View SEC Filing  
2/1/2017William H RastetterDirectorSell10,750$42.28$454,510.00View SEC Filing  
1/17/2017Haig P BozigianInsiderSell1,625$40.63$66,023.75View SEC Filing  
1/17/2017Kevin Charles GormanCEOSell3,750$40.65$152,437.50View SEC Filing  
1/17/2017Timothy P CoughlinCFOSell1,750$40.65$71,137.50View SEC Filing  
1/10/2017Christopher Flint ObrienInsiderSell1,750$43.35$75,862.50View SEC Filing  
1/10/2017Kevin Charles GormanCEOSell3,750$43.28$162,300.00View SEC Filing  
11/15/2016Christopher Flint ObrienInsiderSell25,000$52.84$1,321,000.00View SEC Filing  
9/1/2016Malcolm Lloyd-SmithInsiderSell9,000$50.00$450,000.00View SEC Filing  
8/15/2016Christopher Flint ObrienInsiderSell12,500$48.73$609,125.00View SEC Filing  
8/8/2016Corinne H NevinnyDirectorSell5,000$48.54$242,700.00View SEC Filing  
5/25/2016Richard F PopsDirectorSell15,000$46.72$700,800.00View SEC Filing  
5/16/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  
4/11/2016Kyle GanoInsiderSell41,770$44.02$1,838,715.40View SEC Filing  
4/6/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00View SEC Filing  
2/3/2016Haig P BozigianInsiderSell1,375$38.13$52,428.75View SEC Filing  
2/3/2016Kevin Charles GormanCEOSell3,125$38.04$118,875.00View SEC Filing  
2/3/2016Timothy P CoughlinCFOSell1,500$38.06$57,090.00View SEC Filing  
1/19/2016Haig P BozigianInsiderSell1,625$46.77$76,001.25View SEC Filing  
1/19/2016Kevin Charles GormanCEOSell3,750$46.70$175,125.00View SEC Filing  
1/19/2016Timothy P CoughlinCFOSell1,750$46.69$81,707.50View SEC Filing  
1/11/2016Haig P BozigianInsiderSell1,625$44.25$71,906.25View SEC Filing  
1/11/2016Kevin Charles GormanCEOSell3,750$44.17$165,637.50View SEC Filing  
1/11/2016Timothy P CoughlinCFOSell1,750$44.25$77,437.50View SEC Filing  
11/27/2015Dimitri E. GrigoriadisinsiderSell10,000$57.50$575,000.00View SEC Filing  
11/9/2015Darin LippoldtinsiderSell23,761$52.92$1,257,432.12View SEC Filing  
10/16/2015Haig P BozigianInsiderSell25,000$47.78$1,194,500.00View SEC Filing  
10/16/2015Kevin Charles GormanCEOSell33,500$47.77$1,600,295.00View SEC Filing  
9/18/2015Gary A. LyonsDirectorSell15,000$54.89$823,350.00View SEC Filing  
7/20/2015Dimitri E GrigoriadisInsiderSell19,646$55.00$1,080,530.00View SEC Filing  
7/20/2015Timothy P CoughlinCFOSell20,000$55.00$1,100,000.00View SEC Filing  
7/13/2015Dimitri E GrigoriadisInsiderSell10,000$50.00$500,000.00View SEC Filing  
7/13/2015Timothy P CoughlinCFOSell20,000$50.00$1,000,000.00View SEC Filing  
6/23/2015W Thomas MitchellDirectorSell15,000$49.35$740,250.00View SEC Filing  
6/8/2015Christopher Flint ObrienInsiderSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Timothy P CoughlinCFOSell60,000$45.08$2,704,800.00View SEC Filing  
3/24/2015Gary A LyonsDirectorSell30,000$41.53$1,245,900.00View SEC Filing  
3/24/2015Kevin Charles GormanCEOSell40,000$41.53$1,661,200.00View SEC Filing  
2/10/2015Dimitri E GrigoriadisInsiderSell20,000$35.00$700,000.00View SEC Filing  
1/16/2015Christopher Flint ObrienInsiderSell1,750$30.79$53,882.50View SEC Filing  
1/16/2015Kevin Charles GormanCEOSell3,750$30.79$115,462.50View SEC Filing  
1/12/2015Kevin Charles GormanCEOSell3,750$28.43$106,612.50View SEC Filing  
1/12/2015Kyle GanoInsiderSell1,250$28.41$35,512.50View SEC Filing  
1/12/2015Timothy P CoughlinCFOSell1,750$28.37$49,647.50View SEC Filing  
1/8/2015Dimitri E GrigoriadisInsiderSell30,000$27.35$820,500.00View SEC Filing  
1/8/2015Kevin Charles GormanCEOSell25,000$27.39$684,750.00View SEC Filing  
1/8/2015Timothy P CoughlinCFOSell10,000$27.25$272,500.00View SEC Filing  
1/5/2015Dimitri E GrigoriadisInsiderSell2,500$22.76$56,900.00View SEC Filing  
1/2/2015W Thomas MitchellDirectorSell8,000$22.79$182,320.00View SEC Filing  
12/19/2014Christopher Flint ObrienInsiderSell20,000$24.02$480,400.00View SEC Filing  
12/19/2014Kevin Charles GormanCEOSell70,000$23.41$1,638,700.00View SEC Filing  
12/19/2014Timothy P CoughlinCFOSell30,000$23.46$703,800.00View SEC Filing  
12/17/2014Kyle GanoInsiderSell4,957$22.50$111,532.50View SEC Filing  
12/15/2014Dimitri E GrigoriadisInsiderSell12,794$22.35$285,945.90View SEC Filing  
12/12/2014Kyle GanoInsiderSell4,043$22.50$90,967.50View SEC Filing  
12/11/2014Christopher Flint ObrienInsiderSell40,000$21.82$872,800.00View SEC Filing  
12/10/2014Timothy P CoughlinCFOSell20,000$21.48$429,600.00View SEC Filing  
12/10/2014W Thomas MitchellDirectorSell7,000$21.90$153,300.00View SEC Filing  
11/28/2014Timothy P CoughlinCFOSell10,000$20.14$201,400.00View SEC Filing  
11/24/2014Christopher Flint ObrienInsiderSell5,463$19.53$106,692.39View SEC Filing  
10/31/2014Timothy P CoughlinCFOSell10,000$19.00$190,000.00View SEC Filing  
10/30/2014Timothy P CoughlinCFOSell20,000$18.31$366,200.00View SEC Filing  
10/1/2014W Thomas MitchellDirectorSell1,275$15.50$19,762.50View SEC Filing  
9/15/2014Gary A LyonsDirectorSell20,000$15.66$313,200.00View SEC Filing  
1/17/2014Dimitri GrigoriadisInsiderSell25,000$20.00$500,000.00View SEC Filing  
1/10/2014Christopher Flint ObrienInsiderSell6,750$18.88$127,440.00View SEC Filing  
1/10/2014Kevin Charles GormanCEOSell3,750$18.57$69,637.50View SEC Filing  
1/10/2014Timothy CoughlinCFOSell1,750$18.56$32,480.00View SEC Filing  
1/7/2014Dimitri GrigoriadisInsiderSell25,000$17.50$437,500.00View SEC Filing  
1/7/2014Kevin Charles GormanCEOSell108,000$16.76$1,810,080.00View SEC Filing  
1/7/2014Timothy CoughlinCFOSell70,000$16.75$1,172,500.00View SEC Filing  
9/4/2013Kyle GanoInsiderSell2,400$15.61$37,464.00View SEC Filing  
9/3/2013Christopher Flint ObrienInsiderSell5,000$16.00$80,000.00View SEC Filing  
8/21/2013Haig BozigianInsiderSell13,999$15.04$210,544.96View SEC Filing  
8/21/2013Timothy CoughlinCFOSell19,035$15.05$286,476.75View SEC Filing  
8/6/2013W Thomas MitchellDirectorSell1,531$14.70$22,505.70View SEC Filing  
8/5/2013Haig BozigianInsiderSell11,001$15.00$165,015.00View SEC Filing  
8/5/2013Timothy CoughlinCFOSell10,965$14.99$164,365.35View SEC Filing  
7/12/2013Christopher Flint ObrienInsiderSell5,000$14.50$72,500.00View SEC Filing  
6/28/2013Christopher Flint ObrienInsiderSell11,357$13.33$151,388.81View SEC Filing  
6/27/2013Haig P BozigianInsiderSell8,000$13.00$104,000.00View SEC Filing  
6/21/2013Dimitri E GrigoriadisInsiderSell46,837$12.51$585,930.87View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Neurocrine Biosciences (NASDAQ:NBIX)
Latest Headlines for Neurocrine Biosciences (NASDAQ:NBIX)
DateHeadline logoValuEngine Downgrades Neurocrine Biosciences, Inc. (NBIX) to Strong Sell - May 25 at 3:37 PM logoNeurocrine Biosciences, Inc. (NBIX) Given a $70.00 Price Target by Oppenheimer Holdings Inc. Analysts - May 25 at 3:02 PM logoNeurocrine Biosciences' (NBIX) "Buy" Rating Reaffirmed at Needham & Company LLC - May 24 at 11:26 PM logoNeurocrine Biosciences, Inc. (NBIX) Insider Dimitri E. Grigoriadis Sells 10,000 Shares - May 24 at 7:40 PM logoNeurocrine's Phase 2 Disappointment: Why The Company's Down, But Not Out - May 24 at 6:51 PM logoDid Neurocrine Just Leave The Door Open For Teva In Tourette's? - May 24 at 6:51 PM logoNuerocrine's Tourette's syndrome drug trial fails - May 24 at 10:30 AM logoBiotech Movers: Inovio, Neurocrine, Alnylam - May 24 at 10:30 AM logoInsider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 9,960 Shares of Stock - May 23 at 7:46 PM logoNeurocrine Biosciences Inc. (NBIX) Is Falling After Phase 2 Study Fails - May 23 at 6:17 PM logoNeurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndrome - May 23 at 6:17 PM logoNeurocrine Biosciences, Inc. (NBIX) Stock Rating Reaffirmed by Jefferies Group LLC - May 22 at 12:40 PM logoNeurocrine Biosciences (NBIX) Says INGREZZA Capsules Pharmacokinetic Profile and Long-Term Data to be ... - - May 20 at 8:28 AM logoWhat Drug Approval Means for Neurocrine Biosciences - May 19 at 7:14 PM logoNeurocrine Biosciences (NBIX) Says INGREZZA Capsules Pharmacokinetic Profile and Long-Term Data to be Presented at APA - May 19 at 11:28 AM logoNeurocrine Announces INGREZZA® (valbenazine) Capsules Pharmacokinetic Profile and Long-Term Data to be Presented at the 2017 American Psychiatric Association Annual Meeting - May 19 at 11:28 AM logoFY2017 EPS Estimates for Neurocrine Biosciences, Inc. Cut by Zacks Investment Research (NBIX) - May 15 at 8:40 AM logoNeurocrine Biosciences, Inc. Expected to Post FY2019 Earnings of $0.94 Per Share (NBIX) - May 12 at 6:36 PM logoResearch Analysts Set Expectations for Neurocrine Biosciences, Inc.'s Q2 2017 Earnings (NBIX) - May 12 at 10:25 AM logoNeurocrine Biosciences, Inc. (NBIX) Expected to Post Q2 2017 Earnings of ($0.68) Per Share - May 12 at 9:20 AM logoNeurocrine Biosciences, Inc. (NBIX) Expected to Earn Q2 2017 Earnings of ($0.63) Per Share - May 12 at 9:20 AM logoNeurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference - PR Newswire (press release) - May 12 at 12:16 AM logoNeurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference - May 11 at 7:14 PM logoNBIX: INGREZZA™ Launch Commences… - May 11 at 7:14 PM logoFY2019 Earnings Estimate for Neurocrine Biosciences, Inc. Issued By Oppenheimer Holdings (NBIX) - May 11 at 3:20 PM logoEdited Transcript of NBIX earnings conference call or presentation 9-May-17 9:00pm GMT - May 10 at 6:58 PM logoNeurocrine Biosciences, Inc. (NBIX) PT Raised to $130.00 - May 10 at 8:22 AM logoNeurocrine Biosciences, Inc. (NBIX) Posts Earnings Results - May 9 at 11:03 PM logoEARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q1 Earnings Report - May 9 at 6:25 PM logoInvestor Network: Neurocrine Biosciences, Inc. to Host Earnings Call - May 9 at 6:25 PM logoNeurocrine Biosciences Reports First Quarter 2017 Results - May 9 at 6:25 PM logoNeurocrine reports 1Q loss - May 9 at 6:25 PM logoNeurocrine Biosciences' (NBIX) Buy Rating Reaffirmed at Jefferies Group LLC - May 9 at 9:48 AM logoNeurocrine Biosciences, Inc. (NBIX) Director Sells $269,900.00 in Stock - May 9 at 7:50 AM logoNeurocrine Biosciences, Inc. (NBIX) Coverage Initiated by Analysts at Bank of America Corp - May 6 at 2:40 PM logoPositive Media Coverage Very Likely to Impact Neurocrine Biosciences (NBIX) Stock Price - May 5 at 11:21 PM logoNeurocrine Biosciences, Inc. (NBIX) Receives Average Recommendation of "Buy" from Analysts - May 5 at 8:45 PM logoOppenheimer Holdings Weighs in on Neurocrine Biosciences, Inc.'s Q1 2017 Earnings (NBIX) - May 5 at 7:12 AM logoNeurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results - PR Newswire (press release) - May 4 at 11:51 PM logoNeurocrine Biosciences, Inc. (NBIX) Insider Sells $550,000.00 in Stock - May 3 at 10:38 PM logoInsider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 15,000 Shares of Stock - May 3 at 10:36 PM logoNeurocrine Biosciences, Inc. (NBIX) CEO Kevin Charles Gorman Sells 21,739 Shares - May 3 at 10:32 PM logoNeurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results - May 3 at 5:47 PM logoNeurocrine Biosciences, Inc. (NBIX) Forecasted to Post Q3 2017 Earnings of ($0.69) Per Share - May 3 at 10:53 AM logoNeurocrine Biosciences, Inc. Announces Closing of Offering of $517.5 Million of Convertible Senior Notes - May 3 at 10:35 AM logoNeurocrine Biosciences' (NBIX) "Overweight" Rating Reiterated at Barclays PLC - May 2 at 5:46 PM logoWhy Neurocrine is charging twice as much for its new drug as it said it would - May 2 at 3:43 PM logoNeurocrine Biosciences, Inc. (NBIX) Given "Buy" Rating at Jefferies Group LLC - May 1 at 4:42 PM logoNeurocrine Biosciences (NBIX) Receiving Somewhat Positive Media Coverage, Study Finds - April 28 at 11:40 PM logoNeurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expected - April 27 at 9:55 AM



Neurocrine Biosciences (NBIX) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff